Archivi categoria: MET

CEGF816X2201C

A PHASE II, MULTICENTER, OPEN-LABEL STUDY OF EGF816 IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH EGFR MUTATED NON-SMALL CELL LUNG CANCER AND OF INC280 IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH CMET POSITIVE NON-SMALL CELL LUNG CANCER

STADIO
IV

Il protocollo è attivo nei seguenti centri

Scopri


VISION

TEPOTINIB PHASE II STUDY IN LUNG ADENOCARCINOMA HARBOURING MET EXON 14 (METEX14) SKIPPING ALTERATIONS

STADIO
IIIB/IV

Il protocollo è attivo nei seguenti centri

Scopri




 

CINC280A2201

A PHASE III, MULTICENTER, FOUR-COHORT STUDY OF ORAL CMET INHIBITOR CAPMATINIB (INC280) IN PATIENTS WITH EGFR WILD-TYPE, ADVANCED NSCLC WHO HAVE RECEIVED ONE OR TWO PRIOR LINES OF SYSTEMIC THERAPY FOR ADVANCED/METASTATIC DISEASE (GEOMETRY Mono-1)

STADIO
IIIB/IV

Il protocollo è attivo nei seguenti centri

Scopri